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STUDY PROTOCOL Open Access
Oral esketamine for treatment-resistant
depression: rationale and design of a
randomized controlled trial
Sanne Y. Smith-Apeldoorn1* , Jolien K. E. Veraart1,2, Jeanine Kamphuis1, Antoinette D. I. van Asselt3,
Daan J. Touw4, Marije aan het Rot5 and Robert A. Schoevers1
Abstract
Background: There is an urgent need to develop additional treatment strategies for patients with treatment-
resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic
mixture have been shown repeatedly in this population, but there is still a paucity of data on the efficacy and
safety of (a) different routes of administration, and (b) ketamine’s enantiomers esketamine and arketamine. Given
practical advantages of oral over IV administration and pharmacodynamic arguments for better antidepressant
efficacy of esketamine over arketamine, we designed a study to investigate repeated administration of oral
esketamine in patients with TRD.
Methods: This study features a triple-blind randomized placebo-controlled trial (RCT) comparing daily oral
esketamine versus placebo as add-on to regular antidepressant medications for a period of 6 weeks, succeeded by
a follow-up of 4 weeks. The methods support examination of the efficacy, safety, tolerability, mechanisms of action,
and economic impact of oral esketamine in patients with TRD.
Discussion: This is the first RCT investigating repeated oral esketamine administration in patients with TRD. If shown to
be effective and tolerated, oral esketamine administration poses important advantages over IV administration.
Trial registration: Dutch Trial Register, NTR6161. Registered 21 October 2016.
Keywords: Esketamine, Oral administration, Clinical trial, Treatment-resistant depression
Background
Major depressive disorder (MDD) is one of the most im-
pactful medical conditions worldwide in terms of indi-
vidual suffering, loss of productivity, and health care
costs [1, 2]. Unfortunately, current treatments for de-
pression fail to achieve remission in approximately 30%
of patients [3]. This is known as treatment-resistant de-
pression (TRD).
TRD contributes disproportionately to the disease burden
of MDD. This burden exponentially increases the longer
TRD persists, with increasing risk of impaired functional
and social functioning [4], vast losses in quality of life for
both patients and people close to them [4, 5], and increasing
risk of somatic morbidity [6, 7]. Moreover, TRD is associ-
ated with an impressive financial burden to society, due to
patients’ more extensive and costly use of medical services,
as well as to their loss of productivity [4, 5, 8]. Hence, there
is an urgent need to develop more efficacious therapeutic
strategies for MDD generally, and for TRD specifically.
It has been two decades since a single intravenous (IV)
administration of the anaesthetic agent ketamine was first
reported to have antidepressant effects in patients with
MDD [9]. Since then, accumulating data have confirmed
ketamine’s antidepressant effects [10, 11]. Two features of
these data are most striking. Firstly, response can become
manifest within hours after administration. Secondly, this
response takes place even in patients with TRD.
In most patients, the therapeutic effects of a single IV
administration of ketamine last about 1 week [11, 12].
These effects can be extended with repeated IV
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administration [13–15]. However, this procedure is inva-
sive, costly, and often brings about acute psychiatric
(e.g., dissociation, anxiety, agitation) and somatic (e.g.,
headache, dizziness, cardiovascular) side effects [16].
These disadvantages present major obstacles to clinical
applicability, especially in community settings.
To date, several uncontrolled studies (reviewed by
Schoevers et al. [17] and Rosenblat et al. [18]) and three
small controlled studies [19–21] have reported on the
antidepressant properties of oral ketamine. They suggest
that oral ketamine may also be effective in patients with
TRD, and that side effects are overall more acceptable
compared to IV administration. Besides, data from
chronic pain management indicate that oral ketamine
can often be safely used for longer periods of time, in-
cluding at home [17]. Thus, oral ketamine may be a suit-
able alternative for IV ketamine in the treatment of
TRD. However, the literature on oral ketamine is scarce,
and the bioavailability of oral ketamine has been little
studied. There remains a need to conduct larger con-
trolled studies, and to examine the pharmacokinetics
and pharmacodynamics of oral ketamine [22].
In most TRD studies conducted to date, ketamine has
been administered as a racemic mixture comprised of the
R-(−) enantiomer of ketamine (arketamine) and the S-(+)
enantiomer (esketamine). In the brain, ketamine modulates
glutamate transmission by acting as an N-methyl-D-aspar-
tic acid (NMDA) receptor antagonist. The NMDA receptor
binding affinity of esketamine is three to four times higher
than that of arketamine [23, 24]. As the majority of keta-
mine’s antidepressant properties are believed to stem from
its impact on glutamate neurotransmission, theoretically
esketamine might yield the best therapeutic effect. Indeed,
rapid and robust antidepressant effects of esketamine have
been observed in patients with TRD [25–27]. Besides, com-
pared to racemic ketamine and arketamine, esketamine is
believed to have fewer side effects [26, 28, 29]. To date
there have been no controlled oral esketamine studies.
Ketamine also has other effects that may be linked to
its antidepressant properties. It is used for the treatment
of chronic pain [17] and treatment-resistant anxiety dis-
orders [30], conditions that are often comorbid with
MDD [31, 32]. Besides, ketamine could play a role in
smoking cessation, as the pharmacodynamic effects of
nicotine may involve NMDA receptors [33].
In summary, given (1) the advantages of oral over
IV administration, and (2) pharmacodynamic argu-
ments for a better antidepressant efficacy of esketa-
mine over racemic ketamine and arketamine, oral
esketamine is a promising addition to our currently
available treatment armamentarium for depression. To
investigate repeated administration of oral esketamine
in patients with TRD, we designed a triple-blind ran-
domized controlled trial (RCT).
The primary aim of this RCT is to examine the anti-
depressant properties of oral esketamine in patients with
TRD, as determined using clinician rating scales. Sec-
ondary aims involve the effects of oral esketamine on
self-reported severity of depression, depressive symptom
dimensions, hedonic capacity, suicidal ideation, cognitive
functioning, quality of life, safety, tolerability, and its ef-
fects in specific subgroups of patients. Apart from these
aims, we will address additional relevant questions re-
garding (1) therapeutic effects of oral esketamine on
pain, anxiety and nicotine addiction, (2) its bioavailability
and mechanism of action, and (3) its economic impact.
Methods
Study design
This study features a triple-blind RCT with two parallel
arms, as add-on to regular antidepressant medication: an
esketamine (intervention) group and a placebo (control)
group. The study has a total duration of 10 weeks: 6
weeks of study medication and 4 weeks of follow-up. All
patients who complete the trial are subsequently offered
an off-label esketamine treatment extension. This exten-
sion will be described in more detail elsewhere.
Study management
This study is approved by the Medical Ethics Review
Committee of the University Medical Center Groningen
(UMCG) in the Netherlands (file number M16.198879)
and registered at the Dutch Trial Register (trial number
NTR6161). The independent Clinical Research Office
(CRO) of the UMCG and an independent Data Safety
and Monitoring Board (DSMB) oversee the conduct of
the study. The CRO executes an audit of the trial system
twice a year. The DSMB meets every 6 months to dis-
cuss study progress and patient safety and provide feed-
back to the investigators.
The study is conducted at three centers in the Netherlands:
University Center of Psychiatry in Groningen, Pro Persona
Depression Expertise Center in Nijmegen, and Parnassia Psy-
chiatric Institute in The Hague.
Study treatment
Patients randomized to the intervention arm take cap-
sules containing oral esketamine three times a day dur-
ing 42 consecutive days. During the first 3 days, dosages
are gradually increased from 10mg at administration 1
(day 1) to 30mg at administration 9 (day 3). During the
last 3 days, dosages are gradually decreased from 30mg
at administration 118 (day 40) to 10 mg at administra-
tion 126 (day 42). Patients randomized to the control
arm take placebo capsules containing microcrystalline
cellulose and magnesium stearate. Treatment compli-
ance is assessed during every visit.
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Sample
Recruitment
Psychiatry departments and patient and family associa-
tions throughout the Netherlands are involved in re-
cruitment, and advertisement takes place by various
media. Prior to screening, potential participants receive
an oral and written explanation of study procedures, po-
tential benefits, and potential risks. They are informed
that participation is voluntary and that they are free to
withdraw at any time for any reason. Before enrolment,
written informed consent is obtained from each patient.
Eligibility
Patients are selected for study enrolment based on the
inclusion and exclusion criteria listed in Table 1. During
the study, investigators can decide to withdraw a partici-
pant for urgent medical reasons, or if the situation of a
participant changes such that he or she is no longer eli-
gible to participate.
Statistical power
At the time of sample size calculation, one open-label
study had shown antidepressant effects of oral racemic
ketamine in 57% of patients [39]. Previously, another
open-label study had shown antidepressant effects of
oral esketamine in 50% of patients [40]. This indicates a
response rate of oral (es)ketamine of 50–57%. As the
lack of a control group in these studies might have in-
flated response rates, in the present trial a response rate
of 40% was estimated for the intervention group. For the
control group, a response rate of 15% was estimated.
This was based on previous studies showing a placebo
response in 14.4% of TRD patients [41].
To detect a significant difference in response rate be-
tween groups, with the two-sided significance level set at
95% (α = 0.05) and a power of 0.8, 57 participants per
group should complete the trial. Assuming a 10% drop-
out rate, 64 participants will be included in both groups,
leading to a total of 128 participants.
Randomization and blinding
Participants are randomly allocated in a 1:1 manner to
either treatment group. Randomization is conducted
through ALEA Clinical web application. Blinding takes
place at the level of participants, clinicians, and study
staff. Placebo capsules are matched to esketamine cap-
sules in shape, smell, and colour. All capsules are sealed
in identical blisters. Blisters are labelled as trial medica-
tion, and given a trial number by the manufacturer ACE
Pharmaceuticals. A list with trial medication numbers
and the corresponding allocated treatment is stored at
the Department of Clinical Pharmacy and Pharmacology
of the UMCG. None of the study team members have
access to the list until the trial is finished, or unless
something unexpected happens that warrants breaking
the blind. The success of blinding is tested by asking
participants and data collectors at the end of the inter-
vention period which group they thought participants




All participants are measured before (at baseline), during
(after 1, 2 and 4 weeks), and at the end (after 6 weeks) of
treatment. Additionally, to determine how long therapeutic
effects can be retained, follow-up assessments are planned
after 1 (week 7), 2 (week 8) and 4 (week 10) weeks. All data
are entered electronically. Original study forms are stored
in a secure and accessible place and manner. Figure 1
represents the research procedure schematically.
Primary outcomes
In line with the primary aim of the study, antidepressant
efficacy is measured by 1) response, defined as ≥50% de-
crease in total 17-item Hamilton Depression Rating
Scale (HDRS17) score between pre-treatment and end-
of-treatment; 2) partial response, defined as 25–49%




1. Age 18 to 80 years;
2. Current major depressive episode according to the
DSM-5, ascertained by the MINI;
3. Depression at least moderately severe, defined by a
score > 18 on the HDRS17;
4. TRD, defined as insufficient lifetime response to 3 or
more different classes of antidepressant drugs, given for
at least 4 weeks and in an adequate dose;
5. Stable dose of current antidepressant drug for at least
4 weeks prior to study initiation;
6. Good understanding of spoken and written Dutch.
Exclusion
criteria
1. Meet DSM-5 criteria for current major depressive epi-
sode with psychotic features, bipolar disorder, past or
current psychotic disorder, past or current moderate or
severe substance dependence, or personality disorder as
a primary diagnosis;
2. Recent (within the last 4 weeks) or current use of non-
prescribed psychoactive compounds;
3. Recent (within the last 4 weeks) or current use of
benzodiazepines in excess of 2 mg lorazepam or
equivalent per day;
4. Current electroshock therapy;
5. Active suicidal intent, defined by a score > 2 on item 3
of the HDRS17;
6. Pregnancy or lactation;
7. A relevant somatic disorder, ascertained by physical
examination, electrocardiogram, and blood tests;
8. Use of medication that ketamine interacts with on a
major level according to the Drug Interactions Checker
[34], including monoamine oxidase inhibitors.
DSM-5 5th edition of the Diagnostic and Statistical Manual of Mental Disorders
[35], HDRS17 17-item Hamilton Depression Rating Scale [36, 37], MINI Mini
International Neuropsychiatry Interview [38], TRD
Treatment-resistant depression
Smith-Apeldoorn et al. BMC Psychiatry          (2019) 19:375 Page 3 of 9
decrease in total HDRS17 score between pre-treatment
and end-of-treatment; 3) change in depression symptom
severity, expressed as a change in total HDRS17 score be-
tween pre-treatment and end-of-treatment. The HDRS17
is a 17-item clinician-rated semi-structured interview
[36, 37], that is used to assess the severity of depressive
symptoms. The HDRS17 is completed only by trained
clinicians and researchers. Inter-rater reliability is deter-
mined twice a year: an intraclass correlation coefficient
of > 0.50 (at least moderate agreement) is pursued [42].
Secondary outcomes
The Inventory of Depressive Symptomatology (IDS-SR) is
a 30-item self-report questionnaire that is used to assess
the severity of depressive symptoms as reported by the pa-
tient [43]. The Clinical Global Impression (CGI) is a 2-
item clinician-rated instrument that is used to assess the
overall depression severity (CGI-severity), and the general
effect of therapy on the overall depression severity (CGI-
improvement) [44]. Hedonic capacity is assessed by the
Snaith Hamilton Anhedonia and Pleasure Scale (SHAPS),
a 14-item self-report questionnaire [45]. The SHAPS as-
sesses hedonic capacity separately from other depressive
symptoms, as anhedonia represents a central construct in
MDD with multiple aspects, that is often undervalued in
current MDD severity measurements [46]. The Beck Scale
for Suicide Ideation (BSS) is a 21-item self-report
questionnaire that is used to assess the severity of suicidal
ideation [47] – separately from other depressive symp-
toms, as ketamine might reduce suicidal ideation partly in-
dependent from its effect on MDD in general [48, 49].
Cognitive functioning is measured by the Autobiograph-
ical Memory Test (AMT), involving the presentation of 10
cue words varying in emotional valence. Participants are
asked to respond to each cue with a specific event that the
cue reminds them of [50]. Health related quality of life is
assessed by the 5-level version of the EuroQol 5D (EQ-
5D-5 L), a self-report questionnaire comprising 5 dimen-
sions (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression), complemented with a visual
analogue scale representing general health [51].
Outcomes of adverse events and side effects include the
Questionnaire for Psychotic Experiences (QPE) [52], Dis-
sociation Tension Scale (DSS) [53], Iowa Sleep Disturb-
ance Inventory (ISDI) [54], and Systematic Assessment for
Treatment Emergent Events (SAFTEE) [55]. Safety and
tolerability will also be evaluated via heart rate, blood
pressure, weight, and liver enzyme levels testing.
Outcomes that will be used to identify predictors that
distinguish patients who can benefit from treatment with
oral esketamine include: demographics, the Dutch Meas-
ure for quantification of Treatment Resistance in Depres-
sion (DM-TRD) [56], the NEO Five-Factor Inventory
(NEO-FFI) [57] neuroticism subscale, and the credibility/
expectancy questionnaire (CEQ) [58].
Additional outcomes
Pain is measured by the Graded Chronic Pain Scale
(GCPS) [59], anxiety by the Beck Anxiety Inventory
(BAI) [60], and nicotine dependence by the Fagerström
Test for Nicotine Dependence (FTND) [61].
We will explore the pharmacokinetics of oral esketa-
mine and its main metabolite esnorketamine, and the
genotype of the Cytochrome P450 (CYP) enzymes in-
volved in the metabolism. We will also describe the ef-
fects of esketamine on biomarker patterns and gene
expression patterns that are related to the pathophysi-
ology of depression [62].
Economic evaluation of treatment with oral esketa-
mine as compared to placebo will be conducted from a
societal perspective. A budget impact analysis (BIA) will
be conducted to inform decision-makers about the fi-
nancial consequences of the adoption and diffusion of
treatment with oral esketamine for TRD in the Dutch
healthcare system.
All measures and associated assessment time points
are shown in Table 2.
Statistical analysis plan
The efficacy and safety of esketamine will be tested by the
use of intention-to-treat and per-protocol linear and
Fig. 1 Trial flowchart. Schematic overview of the study design. T:
Number illustrates number of weeks after baseline
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logistic mixed models. The effects on biomarker patterns
will be tested using Receiver Operating Characteristics
(ROC) analyses in combination with phenotype
randomization. Pharmacokinetic models will be built by
using population pharmacokinetic modelling software
(MWPharm) using Iterative-2-stage Bayesian techniques,
and will include the absorption (esketamine) or formation
(esnorketamine) constant, bioavailability, volume of distri-
bution (relative to bioavailability), and total body clearance
(relative to bioavailability). Next, these models will be used
to make an estimation of exposure. These data will be
analysed using descriptive statistics. The relationship be-
tween exposure variables, efficacy and safety will be ex-
plored by using regression models and box-and-whisker
plots.
EQ-5D-5 L data will be converted into Quality Ad-
justed Life Years (QALYs) using the Dutch tariffs [64].
Healthcare resource use, loss of productivity, and infor-
mal care will be recalculated into societal costs accord-
ing to the Dutch guidelines for economic evaluation in
healthcare [65]. Cost-effectiveness and cost-utility will
be reported as incremental costs per point gained on the
HDRS17 and per QALY gained, respectively. Uncertainty
surrounding the outcomes will be assessed by bootstrap
analyses and cost-effectiveness acceptability curves.
Discussion
The current RCT examines the effects of repeated admin-
istration of oral esketamine as add-on to regular anti-
depressant medication in patients with TRD. As such, the
study addresses the urgent need to identify improved
treatment strategies for patients with TRD. The rapid anti-
depressant effects of IV ketamine have been repeatedly
shown in this population, but these effects are mostly
transient and the IV administration has disadvantages.
Several study design considerations merit further dis-
cussion. Firstly, our trial involves oral rather than IV ad-
ministration of ketamine. If proven to be effective, oral
ketamine poses important advantages over IV ketamine.
As previously mentioned, IV administration is costly and
impractical. Moreover, it is inconvenient for patients,
and associated with more side effects than other routes
of administration. This limits the practical utility of IV
ketamine in real-world settings.
Compared to IV ketamine, oral ketamine has a vari-
able and low bioavailability of 17–23% [66, 67]. The ab-
sorption rate of oral ketamine appears to vary
substantially, both between and within patients, possibly
due to variation in gut motility, the state of the stomach,
food intake, and genetic factors [68]. Additionally, oral
ketamine undergoes extensive first-pass metabolism,
which is influenced by individual differences in cyto-
chrome phenotypes. While a low bioavailability may
negatively influence the efficacy of oral ketamine, the
extensive first-pass effects might also have a positive
consequence. Namely, norketamine – ketamine’s main
metabolite – concentrations are relative high after oral
administration of ketamine [68]. In rodent models, nor-
ketamine’s antidepressant effects appear to be similar to
those of ketamine, but they are associated with less be-
havioural and biochemical abnormalities [69]. These
findings suggest that norketamine might serve as an al-
ternative to ketamine. In our oral (es)ketamine study, we
assume that relatively high norketamine levels will be
reached during the steady-state phase. Patients might
subsequently report similar antidepressant effects with
relatively few side effects.
While some oral (es)ketamine studies have shown an
antidepressant effect within hours after administration,
most have shown this only after weeks of treatment [18].
In general a more rapid onset of action with IV rather
than oral administration of antidepressant medication is
not uncommon, understandable from a pharmacological
perspective, and not associated with increased efficacy
[70]. The treatment duration of 6 weeks in our study
was set to be long enough to detect even a delayed anti-
depressant effect. Besides, a longer treatment duration
might enhance the duration of the response to ketamine,
and therefore provide patients a better opportunity to
recover. Previous research indeed suggests a prolonged
response duration after repeated compared to single-
dose ketamine administration (e.g. [13–15, 25]).
Some studies have explored other strategies to extend
the antidepressant effect of a single ketamine dose, for
example by means of lithium, riluzole, or cognitive be-
havioural therapy [71–73]. Continuation with regular
antidepressant medication, as required in this study,
might also contribute to relapse prevention, as is seen in
studies on relapse prevention after index electroconvul-
sive therapy for TRD [74]. Ketamine has been added to
treatment as usual in previous studies [20, 25]. This is
considered safe, as ketamine has no major interactions
with regular antidepressant medications [75].
Both oral and intranasal administration of ketamine
could be suitable alternatives to IV administration, as they
both improve applicability and offer the possibility of self-
administration. Advantages of oral administration over in-
tranasal administration are that the oral route is associated
with the lowest abuse liability [76] and seems the most
practical [22]. In March 2019 the US Food and Drug Ad-
ministration approved an esketamine nasal spray, devel-
oped by Janssen Pharmaceutical Companies of Johnson &
Johnson, for the treatment of TRD. However, as the spray
will only be available via a restricted distribution system,
its accessibility might remain limited [22]. Furthermore,
the costs per patient per month that have been communi-
cated are very substantial [77]. It is therefore still neces-
sary to consider alternative administration routes.
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A second study design consideration that merits further
discussion is that our trial involves esketamine rather than
racemic ketamine. In the Netherlands, as in some other
European countries, only esketamine is available for med-
ical use [78]. As mentioned earlier, compared to racemic
and arketamine, esketamine shows a higher affinity for the
NMDA receptor and might be associated with fewer side
effects. Esketamine might therefore be a more potent and
safer antidepressant. However, which ketamine form is
preferential remains an important research question. We
expect to contribute to this field with the study presented
here. Also of note, while no clinical study to date has dir-
ectly compared the antidepressant properties of the two
enantiomers directly or with the racemic mixture, the first
IV trial is currently being conducted [79].
We derived the daily esketamine dose used in our
study from previous studies on (es)ketamine, including
our pilot study (Smith-Apeldoorn SY, Veraart JKE, Ruhé
HG, Aan het Rot M, De Boer MK, Schoevers RA. Oral
S-ketamine for treating treatment-resistant depression -
a case series. In preparation). Initially, the daily dose was
based on the most commonly studied IV dose of 0.5 mg/
kg racemic ketamine, i.e. 0.25 mg/kg esketamine. If 0.25
mg/kg esketamine accounts for 80% of the NMDA re-
ceptor antagonism and 0.25 mg/kg arketamine accounts
for the remaining 20%, then about 0.3 mg/kg esketamine
counts for similar NMDA receptor antagonism as 0.5
mg/kg racemic ketamine. Assuming a 20% bioavailabil-
ity, a single dose of 1.5 mg/kg oral esketamine should
then equal a single dose of 0.5 mg/kg IV racemic
Table 2 Schedule of assessments
Measurement instruments Assessment target Time pointsa
Baseline Intervention period Follow-up
< T0 T1 T2 T4 T6 T7 T8 T10
Primary and secondary outcomes
HDRS17 Depressive symptoms (clinician-rated) x x x x x x x
IDS-SR Depressive symptoms (patient-rated) x x x x x x x
CGI Overall depression severity and change x x x x x x x
SHAPS Hedonic capacity x x x
BSS Suicidal ideation x x x
AMT Autobiographical memory x x x
EQ-5D-5 L Health related quality of life x x x
QPE Psychotic experiences x x x x
DSS Dissociative features x x x x
ISDI Sleep disturbance x x x x
SAFTEE Side effects in any organ system x x x x x x x x
Physical examination Heart rate, blood pressure, weight x x x x x x x x
Blood collection (I) Liver enzyme levels x x
Demographics questionnaire Demographics x
DM-TRD Treatment-resistance x
NEO-FFI Neuroticism x
CEQ Credibility and expectancy of intervention x
Additional outcomes
BAI Anxiety symptoms x x x
GCPS Pain x x x
FTND Nicotine dependence x x x
Blood collection (II) Biomarkers, gene expression, pharmacokinetics, CYP enzymes x x x x
Urine collection Biomarkers x x x
ZGV Health care consumption x x x
aNumber illustrates number of weeks after baseline. AMT Autobiographical Memory Test, BAI Beck Anxiety Inventory, BSS Beck Scale for Suicide Ideation, CEQ
Credibility/expectancy questionnaire, CGI Clinical Global Impression, CYP Cytochrome P450, DM-TRD Dutch Measure for quantification of Treatment Resistance in
Depression, DSS Dissociation Tension Scale, EQ-5D-5 L EuroQol 5D, FTND Fagerström Test for Nicotine Dependence, GCPS Graded Chronic Pain Scale, HDRS17
Hamilton Depression Rating Scale, IDS-SR Inventory of Depressive Symptomatology, ISDI Iowa Sleep Disturbance Inventory, NEO-FFI NEO Five-Factor Inventory, QPE
Questionnaire for Psychotic Experiences, SAFTEE Systematic Assessment for Treatment Emergent Events, SHAPS Snaith Hamilton Anhedonia and Pleasure Scale,
ZGV Health care use questionnaire (Zorggebruik Vragenlijst) – adapted from the TicP [63] to the context of the current study
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ketamine in NMDA receptor antagonism. However, be-
cause of the repeated administration and the potential
antidepressant properties of esnorketamine, we decided
to reduce the daily dose in our study to 1.25 mg/kg, to
prevent overtreatment and therefore potential unneces-
sary side effects. Evidence for the idea that a dose of
1.25 mg/kg of oral esketamine is potentially effective is
derived from the case report on oral esketamine by
Paslakis et al. [40] and from our pilot study (Smith-Apel-
doorn SY, Veraart JKE, Ruhé HG, Aan het Rot M, De
Boer MK, Schoevers RA. Oral S-ketamine for treating
treatment-resistant depression - a case series. In
preparation).
The dosing regimen in our study is fixed at 90 mg per
day, based on the weights of the average Dutch man and
woman of 84 and 70 kg, respectively [80]. Fixed doses
might facilitate easy translation to a clinical setting. The
daily dose is given in three administrations a day. With
this dosing schedule, high peak blood concentrations
can be prevented. This is expected to minimize acute
side effects, thereby contributing to patient well-being,
continued blinding and applicability. However, there is a
risk of not reaching therapeutic blood levels.
Results from a systematic review by Xu et al. [81] sug-
gest that a single administration of very low-doses of
ketamine (e.g. 0.1 or 0.3 mg/kg IV) is associated with
lower efficacy compared to 0.5 mg/kg IV. It is unclear
whether daily administration of multiple low doses for
several weeks could achieve comparable efficacy. At
present, we do not know whether the defining criterion
for the efficacy of ketamine is the peak blood level of
(nor)ketamine that elicits changes, the administered dose
cumulated per day, or both. Higher sub-anesthetic doses
of ketamine can induce psychotomimetic effects.
Whether a subjective psychedelic experience potentially
has additional therapeutic value, as seen with other hal-
lucinogenic agents [82], requires further investigation
[83]. Blood levels of esketamine and esnorketamine and
psychotomimetic effects will be determined and consid-
ered when analysing the results.
As a final note, we are aware that there is a risk of
long-term side effects with repeated (es)ketamine admin-
istration. Cognitive impairment, uropathy, hepatobiliary
complications, and tolerance are seen in rodent models
and ketamine abusers [84–86]. However, ketamine doses
used in these studies were substantially higher than in
trials with ketamine for TRD or chronic pain [84]. While
we will study side effects closely, further research in
which daily low doses of ketamine (cf. this study) are
directly compared to intermittent use of higher doses
will remain necessary.
Results of our RCT are expected to have potentially
important implications for the care of patients with
TRD. Our data may yield support for the use of oral
esketamine, which could fulfill the urgent need for an
easily applicable, safe, repeatable, and effective treatment
for patients with TRD. Recruitment is on-going. Patient
enrolment started in February 2017 and will continue
until 128 patients are included.
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